Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study [PDF]
, 2017 journal ...
Ashida, Kiyoshi +7 more
core +2 more sources
Therapeutic Advances in Gastroenterology, 2023 Background: Japanese guidelines recommend triple therapy with vonoprazan or a proton pump inhibitor (PPI) in combination with antibiotics to treat Helicobacter pylori ( H. pylori ) infection.
Colin W. Howden +7 more
doaj +1 more source
Potassium-Competitive Acid Blocker-Associated Gastric Hyperplastic Polyps With Severe Bleeding: A Case Series. [PDF]
DEN OpenABSTRACT Gastric hyperplastic polyps can cause gastrointestinal bleeding, and their enlargement has been associated with long‐term acid‐suppressive therapy. Vonoprazan (VPZ), a potassium‐competitive acid blocker, provides potent acid suppression and may induce hypergastrinemia, potentially contributing to the growth of hyperplastic polyps.
Kasuga K +9 more
europepmc +2 more sources
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study [PDF]
, 2017 Objective To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use.Design A phase 3, 24-week ...
Ashida Kiyoshi +8 more
core +2 more sources
Novel Drugs Approved in 2021-2022 [PDF]
, 2022 This article provides an abbreviated overview of the newly Federal Drug Administration (FDA)approved novel drugs of 2021-2022 with their respective approved indication(s).
Do, Michael +3 more
core +2 more sources
A Case of Gastric Neuroendocrine Tumor With a Raspberry-Like Appearance on the Background of Acid-Suppressive Therapy-Related Gastropathy. [PDF]
DEN OpenABSTRACT We report the case of a 52‐year old man who was referred to our institution after a routine health check identified an asymptomatic gastric polyp. The medical history of the patient included reflux esophagitis, for which he had been treated with vonoprazan 10 mg daily for 6 years after initially receiving proton pump inhibitors.
Moriguchi Y +9 more
europepmc +2 more sources
Vonoprazan‐associated long QT syndrome [PDF]
Journal of General and Family Medicine, 2021 To our knowledge, this is the first report describing a case of vonoprazan-associated QT prolongation newly occurring after initiation of the drug and improving after its discontinuation in a patient concurrently receiving polypharmacy including a drug metabolized by CYP3A4.
Kimitoshi Kubo +3 more
openaire +3 more sources
Case Reports in Gastroenterology, 2021 Vonoprazan-associated gastric mucosal redness is rare, and its endoscopic and pathological features remain poorly described. We report 4 cases of vonoprazan-associated gastric mucosal redness, that is, 2 cases each in non-Helicobacter pylori-infected and
Kimitoshi Kubo +5 more
doaj +1 more source
Controversies Regarding Management of Helicobacter pylori Infections [PDF]
, 2023 PURPOSE OF REVIEW: The recognition that Helicobacter pylori should be considered and treated as an infectious disease has yet to fundamentally change diagnostic and treatment practices and has resulted in many controversies.
Graham, David Y +2 more
core +2 more sources
Vonoprazan-based therapy for eradication: experience and clinical evidence
Therapeutic Advances in Gastroenterology, 2016 Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan.
Yuko Akazawa +2 more
doaj +1 more source